

Incentives in diabetic eye assessment by screening

Submission date 01/12/2014	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 25/02/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 07/03/2023	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Diabetes is becoming an increasing health problem around the world. People with diabetes are at risk of sight loss, from a condition called diabetic retinopathy. This happens when tiny blood vessels in the eye bleed, which destroys the retina. It is estimated that in England every year 4,200 people are at risk of blindness caused by diabetic retinopathy and there are 1,280 new cases of blindness caused by diabetic retinopathy. Once people experience symptoms, the disease is already advanced and may be difficult to treat, however, with early diagnosis and treatment, the risk of blindness can be dramatically reduced. In order to prevent avoidable blindness in people with diabetes, eye screening is essential. People with diabetes are invited to eye screening appointments every year. However, rates of attendance at these appointments vary between different areas, and those with the highest risk of sight damage are also those with lowest levels of attendance at screening appointments. The NHS needs simple, inexpensive and cost effective strategies are required by the NHS to influence health behaviours (for example, to increase the number of people attending screening programmes). This has relevance to diabetic eye screening but also more widely as the NHS increasingly tries to prevent disease rather than simply treat it. This study is looking at the impact of different types of financial incentives on encouraging people with diabetes to attend their eye screening appointments. The incentives being tested are a £10 reward, or being entered into a lottery to win £1000.

Who can participate?

People aged sixteen and over with diabetes, who have been invited to eye screening appointments in the past but who have not attended, or tried to rearrange their appointment.

What does the study involve?

People who are eligible for the study are randomly allocated to one of three groups. Participants in the first group (the control group) receive the usual letter, inviting them to an eye screening appointment. Participants in the second group are sent an appointment letter also offering them £10 if they attend their appointment. Participants in the third group are sent an appointment letter, also offering them the opportunity to be entered into a lottery for £1000 if they attend their appointment. The screening procedure involves drops being put into the eye, and a photograph being taken of the eye.

What are the possible benefits and risks of participating?

The benefit of participating is that if a participant is developing diabetic retinopathy, the screening can detect it early, so it can be treated to prevent it leading to blindness. Risks include the eyes being more sensitive to sunlight immediately after the screening procedure and participants should not drive after the appointment, as the drops may affect vision for a short time.

Where is the study run from?

The study is run from the Diabetic Eye Screening Programme managed by 1st Retinal Screen Ltd. There are two screening locations in London, one in Chelsea and Westminster Hospital, and one in St Marys Hospital.

When is the study starting and how long is it expected to run for?

May 2014 to August 2016

Who is funding the study?

National Institute for Health Research (UK)

Who is the main contact?

Mrs Gaby Judah

Contact information

Type(s)

Scientific

Contact name

Mrs Gaby Judah

Contact details

Imperial College London
Division of Surgery
10th Floor, QEQM Building
St Mary's Campus
Praed Street
Paddington
London
United Kingdom
W2 1NY

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

REC 14/LO/1779

Study information

Scientific Title

Incentives in Diabetic Eye Assessment by Screening (IDEAS) Trial

Acronym

IDEAS

Study objectives

1. Are incentives an effective strategy to encourage participation in the screening programme?
2. Does the design of the financial incentive scheme affect its effectiveness in influencing participation in health screening?
3. Does the choice of incentive scheme, if successful, attract patients who have a different demographic or socioeconomic status to those who attend screening regularly?
4. Is offering these incentives a cost-effective strategy for enhancing participation?

Ethics approval required

Old ethics approval format

Ethics approval(s)

National Research Ethics Committee (London - Riverside), 14/10/2014, ref: 14/LO/1779

Study design

Single centre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Screening

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Diabetic retinopathy

Interventions

Participants are randomly allocated to one of three groups:

Group 1 – Control Group: Standard invitation letter from the Screening Service .

Group 2 – Fixed Incentive: Standard invitation letter but with additional text offering a financial

incentive (£10) after screening is completed.

Group 3 – Probabilistic Incentive: Standard invitation letter but with additional text offering a financial incentive (lottery offering 1% chance to win £1000).

Intervention Type

Behavioural

Primary outcome measure

Attendance at the screening appointment. This will be recorded at the appointment (which takes place four weeks after the invitation letter is sent), by the screener entering the patient into the electronic appointment record database. Following the end of data collection a search will be conducted on the database to extract information on attendance, as well as other demographic variables, and information on rearranged appointments.

Secondary outcome measures

1. Assess which incentive scheme is most effective
2. The cost effectiveness of different incentives on increasing uptake.
3. The impact on equity - whether incentives may encourage different groups to attend screening that may otherwise have not. A measure of social deprivation status will be calculated from the postcode. The impact of distance from the screening centre and GP practice will also be considered.
4. The effect of the different interventions on the number of participants who actually consent to the screening procedure once they attend the screening clinic

1st Retinal Screen Ltd will provide the anonymised data including the cohort's age, gender, deprivation status (calculated from postcode), and ethnicity (subject to availability). The data will be provided following the screening of all participants.

If there are significant differences in screening uptake and the demographic/risk factor profile between incentive schemes then a more detailed calculation of the impact of incentives is planned.

Overall study start date

21/05/2014

Completion date

01/08/2016

Eligibility

Key inclusion criteria

Patients, aged 16 and older, who were invited to screening in the last 24 months on a yearly basis and failed to attend or contact the screening service to rearrange an appointment will be studied.

Participant type(s)

Patient

Age group

Other

Sex

Both

Target number of participants

1000

Key exclusion criteria

1. Participants under the age of 16
2. Participants who have attended screening appointments in the past, or contacted the service to rearrange an appointment

Date of first enrolment

02/01/2015

Date of final enrolment

31/12/2015

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

1st Retinal Screen Ltd

London

United Kingdom

W2 1NY

Sponsor information**Organisation**

Imperial College London

Sponsor details

Division of Surgery

10th Floor, QEQM Building

St Mary's Campus

Praed Street

Paddington

London

England

United Kingdom

W2 1NY

Sponsor type

University/education

ROR

<https://ror.org/041kmwe10>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The findings from this study will be disseminated to NHS Diabetic Eye Screening Programme, local stakeholders, and other NHS screening organisations through briefs/newsletters and working paper documents. The findings will be shared with the screening service commissioners NHS England (the commissioners may like to have input into who the findings are shared with).

The trial management group will be responsible for drafting the main reports from the study. Draft copies of any manuscripts will be provided to the Kensington, Chelsea and Westminster Diabetic Eye Screening Programme for review prior to publication.

The main findings will be submitted for publication in peer-reviewed scientific journals and presented in national and international conferences, such as the Annual Meeting & Exposition of the American Public Health Association, and the UK Faculty of Public Health. We will assess both the effectiveness and cost-effectiveness of our financial incentives on uptake to diabetic Eye Screening. We will provide updated information concerning the publication of trial results on a trial-related Web site linked to the trials unit home page. Specialist diabetes and non-specialist

practitioners will be targeted, for example through national society conferences and newsletters. The trial results will, in particular, be shared with the National screening committee. The study results will also be presented to healthcare commissioners and policy makers at appropriate meetings and publications. A summary of results, in language appropriate for lay persons, will be sent to all relevant patient groups.

Intention to publish date

01/06/2016

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	18/03/2016		Yes	No
Results article	results	01/03/2017		Yes	No
Results article		23/08/2018	07/03/2023	Yes	No
HRA research summary			28/06/2023	No	No